Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QuantaRx's follicle stimulating hormone immunoassay:

This article was originally published in Clinica

Executive Summary

The lateral flow immunoassay, called the QuantRx Biomedical Female Fertility test, is intended to aid women who are attempting to conceive. It can indirectly determine ovarian reserve - a measure of the capacity of the ovary to provides eggs that are capable of fertilisation - by measuring FSH in first morning urine. The over-the-counter test can produce results within 15 minutes, and can detect levels of FSH as low as 10ng/ml. The company is also developing a male fertility test, which is expected to reach the market in 2008.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel